Adult Open Studies

COVID-19 - APPOINTMENTS AND PROCEDURES

Your health and safety is still our top priority. Appointments are available as video visits, phone calls or in-person visits as needed, with the same safe, world-class care you expect.

Schedule Now

Biology

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION

Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol

Mark E. Reeves, MD, PhD

Brain

SWOG-NRG-BN001

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT02179086

Joseph Kang, MD

Investigator Initiated-AXUMIN

Differentiating glioma recurrence from treatment-induced necrosis using 18F-fluciclovine (anti-18f-facbc) PET and Multiparametric MR Imaging
https://clinicaltrials.gov/ct2/show/NCT03925675

Warren Boling, MD

SWOG-EAF151

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03115333

Muhammad Kamal, MD

Breast

NSABP-B51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT01872975

Sharon Lum, MD

Investigator Initiated GRASP-CIPN

A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy.
https://clinicaltrials.gov/ct2/show/NCT03272919

Gayathri Nagaraj, MD

SWOG-S1418-BR006

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Cancer
https://clinicaltrials.gov/ct2/show/NCT02954874

Gayathri Nagaraj, MD

SWOG-BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03199885

Gayathri Nagaraj, MD

NIH NIMHD-IGF II (Resvida)

Mechanisms in IGF-II induced Chemoresistance and Mitochondrial regulation in TNB

Gayathri Nagaraj, MD

GI

Bowel

SWOG-S1316

Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
https://clinicaltrials.gov/ct2/show/NCT02270450

Maheswari Senthil, MD

Colon

SWOG-S0820

Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification
https://www.clinicaltrials.gov/ct2/show/NCT03365882

Chung-Tsen Hsueh, MD, PhD

SWOG-S1613

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
https://www.clinicaltrials.gov/ct2/show/NCT01349881

Chung-Tsen Hsueh, MD, PhD

Esophagus

Radiation Medicine

A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904

Gary Yang, MD

Gastric

Astellas-8951-CL-0301

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03504397

Chung-Tsen Hsueh, MD, PhD

Liver

Radiation Medicine

Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases
https://clinicaltrials.gov/ct2/show/NCT01697371

Gary Yang, MD

QED-QBGJ398-301

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
https://clinicaltrials.gov/ct2/show/NCT03773302

Chung-Tsen Hsueh, MD, PhD

NeuWave- NEU-2017-04

A Multicenter Observational Registry to Develop Abation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions
https://clinicaltrials.gov/ct2/show/NCT04107766

Roger Tomihama, MD

Pancreas

Investigator Initiated

A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic https://clinicaltrials.gov/ct2/show/NCT03492671

Naveenraj Solomon, MD

GU

Prostate

Radiation Medicine

A prospective comparative study of outcomes with proton and photon radiation in prostate cancer
https://clinicaltrials.gov/ct2/show/NCT00831623

Jerry Slater, MD

Urethra

Adelphi Values-VK8373AUS

Patient Experience in Treatment for Low-grade Upper Tract Urothelial Carcinoma

Brian Hu, MD

SWOG-A031501

hase III randomized “Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADva nced urOthelial caRcinoma” (AMBASSADOR) versus observation
https://clinicaltrials.gov/ct2/show/NCT03244384

John Wong, MD

GYN

Multiple

Investigator Initiated-Paclitaxel

Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in gynecologic-oncology patients: A prospective, randomized, open-label study
https://clinicaltrials.gov/ct2/show/NCT03598426

Linda Hong, MD

SWOG-GY019

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
https://clinicaltrials.gov/ct2/show/NCT04095364

JYevgeniya Ioffe, MD

Ovarian

Investigator Initiated HIPEC

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02672098

Mazdak Momeni, MD

Cervical

GOG-0263

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
https://clinicaltrials.gov/ct2/show/NCT01101451

Yevgeniya Ioffe, MD

Uterine

GOG-0238

A Randomized Trial Of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients With Pelvic-Only Recurrence Of Carcinoma Of The Uterine Corpus
https://clinicaltrials.gov/ct2/show/NCT00492778

Linda Hong, MD

Head and Neck

Soligenix-IDR-OM-02

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
https://clinicaltrials.gov/ct2/show/NCT03237325

Huynh Cao, MD

Leukemia

SWOG-A041701

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
https://clinicaltrials.gov/ct2/show/CT03701308

Muhammad O. Kamal, MD

Lung

SWOG-LU003

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
https://clinicaltrials.gov/ct2/show/NCT03737994

Hamid Mirshahidi, MD

SWOG-A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
https://clinicaltrials.gov/ct2/show/NCT02194738

Hamid Mirshahidi, MD

SWOG-A081105

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT02194738

Hamid Mirshahidi, MD

SWOG-E4512

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
https://clinicaltrials.gov/ct2/show/NCT02201992

Hamid Mirshahidi, MD

SWOG-LUNGMAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
http://clinicaltrials.gov/ct2/show/NCT02154490

Hamid Mirshahidi, MD

Lymphoma

SWOG-A051301

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
https://clinicaltrials.gov/ct2/show/NCT02443077

Muhammad O. Kamal, MD

SWOG-S1608

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03269669

Muhammad O. Kamal, MD

Melenoma

SWOG-S1801

A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma (NCT #03698019)
https://clinicaltrials.gov/ct2/show/NCT03698019

Mark E. Reeves, MD, PhD

Multiple

SWOG-EAY131-MATCH

Molecular Analysis for Therapy Choice (MATCH)
https://clinicaltrials.gov/ct2/show/NCT02465060

Gayathri Nagaraj, MD

SWOG-S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02834013

John Wong, MD

COG-AGCT1532

A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors
https://clinicaltrials.gov/ct2/show/NCT02582697

John Wong, MD

Soft Tissue Sarcoma

Radiation Medicine

A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall
https://clinicaltrials.gov/ct2/show/NCT01819831

Gary Yang, MD

Registry

Radiation Medicine

Radiation Medicine Patient Registry
https://clinicaltrials.gov/ct2/show/NCT02436941

Jerry Slater, MD

Penn State-Colon Registry

Prospective observational database of patients with colon cancer at risk of peritoneal recurrence

Maheswari Senthil, MD

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050

Open and Safe During COVID-19

Keyword Search

Services & Treatments

Provider Search

Location Search

Adult Open Studies